By Natalie Grover LONDON (Reuters) - Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability .
Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.
European Alzheimer s experts unconvinced by new Eisai, Biogen drug – The Frontier Post thefrontierpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thefrontierpost.com Daily Mail and Mail on Sunday newspapers.